Cocrystal Pharma, Inc. (COCP) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-30

Key Insights

Cocrystal Pharma presented clinical data on CDI-988, its first oral protease inhibitor, at a major international antiviral research conference, indicating advancement of a potentially significant pipeline asset.
The presentation at ICAR 2026 in Prague featured both mechanism of action and clinical advancement details, suggesting the compound has progressed beyond early-stage development and may be approaching later clinical phases.
This is a Regulation FD disclosure with no material financial impact disclosed, representing routine investor relations activity rather than a material business event.
The filing was signed by James Martin as Co-Chief Executive Officer and Chief Financial Officer, indicating dual leadership structure at the company.

Want the newest filings?

This analysis covers the filing from 2026-04-30. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-31

Cocrystal Pharma announced its fiscal year 2025 results, providing an update on the company's operations and financial performance.
The company did not provide any forward-looking guidance or details on new product development or regulatory milestones.
Without additional information on the company's plans and pipeline, it is difficult to assess the long-term growth prospects for Cocrystal Pharma.

Filed: 2026-02-19

Cocrystal Pharma announced the development of its first oral norovirus protease inhibitor CDI-988, which will be featured at the upcoming ICAR 2026 conference in Prague.
The company's focus on developing a norovirus treatment indicates potential growth opportunities in the antiviral drug market.
Investors should monitor the progress and data presented on CDI-988 at the ICAR conference for insights into the compound's development and potential future commercialization.

Filed: 2026-01-15

Cocrystal Pharma granted stock options to its directors, executive officers, and a consultant, indicating potential alignment of interests between management and shareholders.
The stock options have a 10-year term and vest over time, which could incentivize long-term performance and retention of key personnel.
The company also awarded a $50,000 cash bonus to the chairman of its Scientific Advisory Board, suggesting the importance of scientific expertise to Cocrystal's business.

Other reports for Cocrystal Pharma, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.